APLLTD - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.2
| Stock Code | APLLTD | Market Cap | 12,894 Cr. | Current Price | 655 ₹ | High / Low | 1,108 ₹ |
| Stock P/E | 25.4 | Book Value | 267 ₹ | Dividend Yield | 1.68 % | ROCE | 11.3 % |
| ROE | 9.68 % | Face Value | 2.00 ₹ | DMA 50 | 754 ₹ | DMA 200 | 858 ₹ |
| Chg in FII Hold | 0.19 % | Chg in DII Hold | -0.13 % | PAT Qtr | 149 Cr. | PAT Prev Qtr | 179 Cr. |
| RSI | 21.3 | MACD | -28.0 | Volume | 54,061 | Avg Vol 1Wk | 48,961 |
| Low price | 652 ₹ | High price | 1,108 ₹ | PEG Ratio | -7.70 | Debt to equity | 0.27 |
| 52w Index | 0.76 % | Qtr Profit Var | 74.0 % | EPS | 24.0 ₹ | Industry PE | 27.2 |
📊 Analysis: APLLTD shows moderate fundamentals with ROE at 9.68% and ROCE at 11.3%, which are below ideal levels for long-term investment. The P/E ratio of 25.4 is slightly below the industry average of 27.2, suggesting fair valuation. Dividend yield at 1.68% adds modest income potential. Debt-to-equity at 0.27 is manageable, though not negligible. The PEG ratio of -7.70 indicates weak growth prospects relative to valuation. Technical indicators (RSI 21.3, MACD negative, price below DMA 50 & 200) show strong bearish momentum. Overall, the company is fairly valued but weak in growth metrics, making it a cautious candidate for long-term investment.
💰 Ideal Entry Zone: ₹640 – ₹670, closer to support levels, aligning with current bearish sentiment and valuation comfort.
📈 Exit / Holding Strategy: Existing holders should maintain a medium-term horizon (2–3 years) but monitor earnings closely. Consider partial profit booking if the price revisits ₹850–₹900. Long-term holding is not recommended unless ROE/ROCE improve significantly and growth stabilizes.
Positive
- Debt-to-equity at 0.27 indicates manageable leverage.
- Dividend yield of 1.68% provides modest income potential.
- EPS at ₹24 supports earnings visibility.
- FII holdings increased (+0.19%), signaling some foreign investor confidence.
Limitation
- Weak ROE (9.68%) and ROCE (11.3%) highlight poor capital efficiency.
- PEG ratio of -7.70 indicates weak growth prospects.
- Technical indicators (RSI 21.3, MACD negative) show strong bearish momentum.
Company Negative News
- Quarterly PAT declined (₹149 Cr vs ₹179 Cr), showing earnings weakness.
- DII holdings decreased (-0.13%), reflecting reduced domestic institutional confidence.
Company Positive News
- Quarterly profit variance at 74% highlights operational improvement despite recent decline.
- Stable valuation compared to industry average P/E (25.4 vs 27.2).
Industry
- Industry P/E at 27.2 is slightly higher than company’s P/E (25.4), suggesting fair valuation.
- Pharmaceutical sector growth supported by healthcare demand and exports, though competition remains high.
Conclusion
⚖️ APLLTD is moderately strong but lacks robust growth metrics, making it a cautious candidate for long-term investment. Ideal entry is around ₹640–₹670. Existing holders should maintain a 2–3 year horizon, booking profits near ₹850–₹900. While dividend yield and fair valuation provide some comfort, weak ROE/ROCE and bearish technicals warrant cautious positioning.